- Home
- NTHI vs SLS Comparison
NTHI vs SLS Comparison
Compare NTHI & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTHI | SLS |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 243.9M | 706.7M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | NTHI | SLS |
|---|---|---|
| Price | $9.50 | $5.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 29.7K | ★ 5.9M |
| Earning Date | 01-01-0001 | 04-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.69 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.20 | $0.95 |
| 52 Week High | $16.00 | $6.14 |
Technical Indicators
Market Signals| Indicator | NTHI | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 42.17 | 59.48 |
| Support Level | $8.29 | $1.48 |
| Resistance Level | $10.52 | N/A |
| Average True Range (ATR) | 0.66 | 0.53 |
| MACD | -0.11 | 0.01 |
| Stochastic Oscillator | 11.89 | 60.96 |
Price Performance
Historical ComparisonAbout NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.